Implantica Expands RefluxStop™ Program with New Centers

Implantica Expands RefluxStop™ Network in Spain

Implantica AG, a pioneering medtech company, has recently completed the onboarding of two prestigious University Hospitals in Spain as RefluxStop™ Centers of Excellence. This milestone raises the number of active centers to ten, dramatically enhancing the accessibility of the RefluxStop™ procedure for patients seeking relief from gastroesophageal reflux disease (GERD).

Innovative Treatment for GERD

The RefluxStop™ device stands out in the field of treatments for acid reflux, which affects a staggering one billion individuals globally. Dr. Mar Viana Miguel, the leading foregut surgeon at Hospital Universitario Burgos in Spain, successfully conducted the inaugural RefluxStop™ procedures at their facility. Dr. Viana expresses her enthusiasm, highlighting how this new approach opens doors for patients who previously had limited options for effective GERD treatment.

Transforming Surgical Care

Dr. Viana remarked, "We are embarking on a revolutionary path in surgical treatment for GERD. Many patients have struggled with traditional solutions, and the RefluxStop™ device offers them a promising alternative that delivers notable long-term results based on clinical studies." This sentiment reflects a growing acknowledgment of the dire need for innovative solutions in this medical field.

Growing Network of Centers in Spain

Another prominent addition to the RefluxStop™ network is the Universitario Santa Lucia Hospital in the Murcia region. Renownedforegut surgeon Dr. Inmaulada Navarro has performed groundbreaking procedures at this hospital. Dr. Navarro expressed her gratitude to the hospital's management for their support in integrating this cutting-edge technology.

Improving Patient Outcomes

Dr. Navarro emphasized, "We are committed to providing our GERD patients with a reliable and sustainable surgical treatment option. The success rates observed in clinical trials involving over a thousand patients across leading European nations have been exceptional." Her enthusiasm encapsulates the optimism surrounding the RefluxStop™ treatment as a game-changer in the management of GERD.

Vision for the Future

The inventor of the RefluxStop™, Dr. Peter Forsell, who also leads Implantica, shared insights on the device's impact. He mentioned that roughly 15% of the adult population in Spain suffers from GERD, leading to a continuous reliance on anti-reflux medications. Dr. Forsell expressed excitement about the acceptance of RefluxStop™ technology within Spain's medical community, reinforcing the commitment to training additional hospitals eager to adopt this innovative treatment.

Significance of RefluxStop™

Dr. Forsell stated, "RefluxStop™ represents a transformative advancement in GERD treatment for generations to come. We anticipate expanding our partnerships with skilled surgeons, aiming to bring this effective procedure to countless patients in need of relief from their symptoms." His optimism is reflective of the broader potential for healthcare advancements in Spain and beyond.

About Implantica AG

Implantica AG is a dedicated medtech organization focused on advancing healthcare through innovative technology. Its flagship product, RefluxStop™, is a CE-marked implant designed specifically for the prevention of gastroesophageal reflux. With its groundbreaking approach, it aims to redefine standards of care for patients suffering from acid reflux.

Overview of RefluxStop™ Technology

RefluxStop™ differentiates itself with its unique mechanism of action, addressing the root causes of acid reflux without applying pressure on the esophagus. It aims to support the natural anatomical structures, allowing the body to restore its functions effectively. This innovative approach holds the promise of enhancing patient comfort and outcomes.

Frequently Asked Questions

What is the RefluxStop™ device?

RefluxStop™ is an innovative medical device designed to treat gastroesophageal reflux disease (GERD) through minimally invasive surgical techniques.

How many centers are currently offering RefluxStop™?

Currently, there are ten active RefluxStop™ Centers of Excellence in Spain, with more hospitals in the pipeline to adopt this innovative procedure.

Who are the key surgeons involved with RefluxStop™?

Prominent foregut surgeons such as Dr. Mar Viana Miguel and Dr. Inmaulada Navarro are leading the way in implementing the RefluxStop™ technology in Spain.

What are the benefits of using RefluxStop™ compared to traditional treatments?

RefluxStop™ aims to provide a more effective solution for GERD symptoms without the side effects associated with traditional surgical methods, supporting the body’s physiological functions.

Is Implantica publicly traded?

Yes, Implantica AG is listed on the Nasdaq First North Premier Growth Market in Stockholm.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.